There is curious divergence between achievements of practical geriatrics and experimental gerontology. On the one hand, the consumption of brain protective, stimulative and regenerative drugs is expanding in elderly population. During last 30 years physicians in many developed countries have successfully prescribed a number of medicines to cure various symptoms of senescence. Most common of relevant medicines are nootropic piracetam and gamma-aminobutyric acid (GABA), selegiline, ginkgo biloba, cerebrolysin, solcoseryl, ergoloid, vinpocetin, sertraline, and some others. Available data from human clinical practice and experimental animal studies strongly suggest that treatment with these drugs does improve learning, memory, brain metabolism and capacity, increase tolerance to various stresses such as oxygen deficit and exercise, stimulate regeneration of neurons in old brain, and speed up performing mental and physical tasks. This means that modern medicine already has "anti-aging" therapies in its disposal. On the other hand, the influence of such "anti-aging" treatment on mean and maximal life span, and, more sophisticatedly, on age trajectory of a survival curve has practically not been studied in humans. It is recognized that the increase in human life expectancy at birth in the second half of last century was mostly due to better survival in the old and oldest old ages rather than in young ages. We provide evidence supporting the idea that the consumption of medicines exerting anti-aging properties could partly be responsible for the increase in human longevity.
legal anti-aging medicines